Current Meeting     Our Mission     Future & Past Programs      Sponsorship     Board of Directors     Contact Us
Meeting Announcement
-->
Date: Wednesday, January 24th, 2018
Topic: "Normal and Neoplastic Stem Cells"
Speaker: Irving Weissman, M.D.
Director, Institute of Stem Cell Biology and Regenerative Medicine
Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine
Professor of Pathology and Developmental Biology
Co-Founder and Board Member, Forty Seven Inc
Stanford University School of Medicine
Location:

The Holiday Inn
275 S Airport Blvd
South San Francisco, CA 94080
650-873-3550 | Map
Next door to the SSF Conference Center
Directions at www.hisfo.com

Price:

$50 before 9PM, Monday, January 22nd
$60 on-site
$40 full-time students pre-registration
$50 full-time students on-site
$3 service fee will be added to the pre-registration price

6:00 PM - networking
7:00 PM - dinner
8:00 PM - presentation

Gold Sponsors

CDD
Dsg
Fisher Clinical
ReImagine Science
PharmaLegacy
ClinCapture
HitGen
AltScience
Jubilant

Silver Sponsors

WAVSIP
Selvita
Applied

Location Sponsor

Pii

Abstract:

TBD

Biography:

Dr. Irving L. Weissman is a Professor of Pathology and Developmental Biology at Stanford University where he is the Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. He is a leader in the field of cancer stem cell biology and is an expert in the field of hematopoiesis, leukemia, and hematopoietic stem cells [HSC], and most recently, the clonal events leading from HSC to leukemia stem cells. His research also encompasses the phylogeny and developmental biology of the cells that make up the blood-forming and immune systems.

His laboratory was first to identify and isolate the blood-forming stem cell [HSC] from mice, and has defined, by lineage analysis, the stages of development between the stem cells and mature progeny. His laboratories have also discovered the human HSC, a human brain-forming stem cell population, mouse skeletal muscle stem cells, and an osteochondral stem cell in mice. In recent years his work has included studying the potential of CD47 as a cancer therapeutic and identifying cancer stem cells from a variety of blood and solid cancers. He and his colleagues have found that CD47, a "don't eat me" signal is highly expressed beginning in the latter stages of progression of cancer stem cells from the benign to the highly malignant state, and this counteracts "eat me" signals on preneoplastic and highly malignant cancer cells, presumably as part of the evolution of cancer clones driven by self-renewing subsets of cells in the cancer. This research brings into focus the primary role of phagocytic cells such as macrophages of the innate immune system, in tumor surveillance.

Dr. Weissman has trained and supervised hundreds of students and fellows, authored more than 750 scientific articles and has numerous awards and honorary degrees for his research accomplishments. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and many other societies. He is past president of the American Association of Immunologists [1994] and the International Society of Stem Cell Research [2009].

Dr. Weissman was a co-founder of three companies, SyStemix, Cellerant, and Stem Cells, Inc., all focused on bringing stem cell therapies into the clinic, and earlier was on the founding SABs of Amgen, DNAX, and T Cell Sciences. He is a co-founder and board member of Forty Seven, Inc. He obtained an M.D. from Stanford University.

Registration Policy    Registration via CEvent     Map
-->
© BioSF.org ALL RIGHTS RESERVED BioScience Forum